Crossmark

White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example

Crossref DOI link: https://doi.org/10.1007/s12325-021-01996-0

Published Online: 2022-01-05

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jackisch, Christian http://orcid.org/0000-0001-8537-3743
Manevy, Federico http://orcid.org/0000-0003-3877-2324
Frank, Suzanne http://orcid.org/0000-0001-5081-4000
Roberts, Nicki http://orcid.org/0000-0002-7258-723X
Shafrin, Jason http://orcid.org/0000-0001-8444-5979
Funding

Funding for this research was provided by:

Health Interactions
License Information

Text and Data Mining valid from 2022-01-05

Version of Record valid from 2022-01-05
More Information

Article History

Received: 14 October 2021

Accepted: 12 November 2021

First Online: 5 January 2022

Change Date: 5 February 2022

Change Type: Update

Change Details: This article has been revised due to error in text.

Document is current

Any future updates will be listed below